FT-576

N/A

Report date: 2022/09/06 18:12:16

Base Information

Drug NameFT-576
Drug Alias NameFT-576
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III-A agonistsAnti-BCMAAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsLow affinity immunoglobulin gamma Fc region receptor III-AB-cell maturation protein
Therapy Area/IndicationsBone Marrow NeoplasmsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of MinnesotaFate Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of MinnesotaFate Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsBone Marrow NeoplasmsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A